TY  - JOUR
AU  - Albrecht, Philipp
AU  - Karabati, Ekin
AU  - Ebert, Matthias P
AU  - Betge, Johannes
TI  - Gastric cancer: from biomarkers to functional precision medicine.
JO  - Trends in molecular medicine
VL  - nn
SN  - 1471-4914
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2025-01276
SP  - nn
PY  - 2025
N1  - #EA:B440#LA:B440# / epub
AB  - Gastric cancer (GC) remains a deadly disease because of late detection and limited treatment options at advanced stages. Treatment of patients with metastatic disease is based on chemotherapy, complemented by antibodies targeting HER2, VEGFR2, and more recently PD-1 or claudin 18.2. Further targets, such as FGFR2b, as well as novel drug classes including antibody-drug conjugates (ADCs) and bispecific antibodies, are promising developments in GC treatment. Despite the failure of several targeted agents, the landscape of GC therapy is evolving rapidly, facilitated by umbrella or platform precision medicine trials. The integration of next-generation sequencing and other omics techniques into molecular tumor boards, as well as functional drug testing on patient-derived models, might bring us closer to personalized oncology and ultimately improve patient survival.
KW  - functional precision medicine (Other)
KW  - gastroesophageal adenocarcinoma (Other)
KW  - immunotherapy (Other)
KW  - patient-derived organoids (Other)
KW  - precision oncology (Other)
KW  - targeted therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40555635
DO  - DOI:10.1016/j.molmed.2025.05.007
UR  - https://inrepo02.dkfz.de/record/302158
ER  -